Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 61, Issue 21, Pages 9429-9441Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.8b00598
Keywords
-
Categories
Funding
- SYSU [3600018831104, 36000-18831102]
- Guangdong Innovative and Entrepreneurial Research Team Program [2016ZT06Y337]
Ask authors/readers for more resources
PRA/ITS is a major enzyme responsible for symmetric dimethylation of arginine residues on both histone and non-histone proteins, regulating many biological pathways in mammalian cells. PRMT5 has been suggested as a therapeutic target in a variety of diseases including infectious disease, heart disease, and cancer. Many PRMT5 inhibitors have been discovered in the past 5 years, and one entered clinical trial in 2015 for the treatment of solid tumor and mantle cell lymphoma (MCL). The aim of this review is to summarize the current understanding of the roles of PRA/ITS in cancer and the discovery of PRMT5 enzymatic inhibitors. By reviewing the structure-activity relationship (SAR) of known inhibitors of PRMT5, we hope to provide guidance for future drug designs and inhibitor optimization. Opportunities and limitations of PRMT5 inhibitors for the treatment are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available